Compare NEXT & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEXT | RCKT |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 340.9M |
| IPO Year | N/A | N/A |
| Metric | NEXT | RCKT |
|---|---|---|
| Price | $5.47 | $3.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 14 |
| Target Price | $9.00 | ★ $29.12 |
| AVG Volume (30 Days) | ★ 3.2M | 2.3M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.16 | $2.19 |
| 52 Week High | $12.12 | $13.50 |
| Indicator | NEXT | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 38.22 | 52.07 |
| Support Level | $6.11 | $3.30 |
| Resistance Level | $6.44 | $3.65 |
| Average True Range (ATR) | 0.30 | 0.19 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 3.05 | 66.22 |
NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.